Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment By Ogkologos - December 12, 2025 358 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the interim analysis of the DESTINY-Breast05 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR FDA Approves Penpulimab-kcqx for Non-keratinizing Nasopharyngeal Carcinoma May 23, 2025 Implementation of Molecular Tumour Board Portal Developed Under the Umbrella of... May 25, 2022 Dabrafenib–Trametinib Combination Approved for Melanoma, Anaplastic Thyroid Cancer May 25, 2018 Study Suggests Watching Disney Movies May Improve Quality of Life for... May 26, 2020 Load more HOT NEWS Research with integrity – the importance of communication Opinion: ‘Let’s not be short-sighted – the UK’s medical research charities... Her Massive Weight Loss Helped Her Feel A Lump In Her... “That is what I dream”: India’s journey to rolling out the...
